Man Group
ACOR

Man Group’s Acorda Therapeutics ACOR Stock Holding History

Man Group’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,191
Closed -$1.1M – 1958
2019
Q2 		$1.1M Sell
1,191
-2,482
-68% -$3.05M ﹤0.01% 1498
2019
Q1 		$5.86M Buy
3,673
+2,553
+228% +$4.6M 0.02% 829
2018
Q4 		$2.09M Buy
1,120
+379
+51% +$825K 0.01% 1200
2018
Q3 		$1.75M Buy
741
+696
+1,547% +$2.15M 0.01% 1471
2018
Q2 		$155K Buy
+45
New +$138K ﹤0.01% 2044

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Man Group's ACOR Position: Q3 2019 in Review

Man Group sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 1,191 shares — an estimated $1.1M sold.

Man Group first reported a position in ACOR in Q2 2018 and held it in 5 quarters. The position peaked at $5.86M in Q1 2019. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • Man Group reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Man Group sold 1,191 Acorda Therapeutics shares in Q3 2019, an estimated $1.1M.
  • Man Group first reported a position in Acorda Therapeutics in Q2 2018 and held it in 5 quarters.
  • Man Group's Acorda Therapeutics position peaked at $5.86M in Q1 2019.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Man Group's 13F filing for Q3 2019, filed 14 Nov 2019.